Conclusion: The present animal experiment supported that the antidromically evoked facial nerve response (AFNR) was useful for the early diagnosis of facial palsy and for assessing its recovery course. Objective: Chronological changes of AFNR latencies after nerve damage were investigated to examine whether or not AFNR latency was suitable as a parameter for the assessment of facial nerve function. Materials and Methods: AFNR were recorded in guinea pigs with and without the total or partial transection of the facial nerve. Chronological changes of AFNR after facial nerve transection were investigated. Results: 48 h after the total transection, the responses almost completely disappeared, and reappeared after 3 weeks. The latencies of the recovered responses were prolonged then but shortened thereafter. Meanwhile, the partial transection did not result in a total loss of AFNR, but in a decrease of the amplitude and prolongation of the latency. One day after the partial transection, the latencies of the responses had already prolonged. From the 3rd to the 7th day, the latencies progressively prolonged, and then shortened by the 14th day.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.